ArticleCureus2026
Facial Adipostructuring With Biochemical Modulation in Chronic Peripheral Facial Paralysis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic peripheral facial paralysis (CPFP) implies a prolonged course without recovery of neuromuscular activity of facial expression and the biological impossibility of restoring spontaneous function. Facial paralyses, most commonly idiopathic in origin, are graded using the House-Brackmann (HB) scale, where grade I represents normal function and grades II through VI indicate progressively greater functional compromise. Furthermore, CPFP lacks satisfactory therapeutic options, and conventional strategies, botulinum toxin and surgical reanimation, neither address the collapse of facial structural support nor the dysfunction of dermal white adipose tissue (dWAT) that accompanies chronic denervation. This report presents a treatment strategy for patients with CPFP consisting of Facial Adipostructuring (AEF), a biomechanical reorganization of fat compartments via cannula-based mechanotransduction without tissue extraction, combined with biochemical modulation using dimethylaminoethanol (DMAE), organic silicon, and acetyl hexapeptide-38. The patient progressed from HB grade IV to grade I over three biweekly sessions, with improvement sustained at nine-month follow-up without additional interventions. The changes observed were consistent with improvements on the HB functional scale and were documented through standardized clinical photography. This treatment represents a minimally invasive regenerative approach that may act on the neuro-muscular-adipose unit through dWAT mechanotransduction and neuromuscular junction modulation. We present the case of a female patient with idiopathic facial paralysis of six years' duration, classified as grade IV on the HB scale, who was treated with the described technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.